Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease

NCT02274415 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

116

Enrollment

OTHER

Sponsor class

Conditions

Invasive Pneumococcal Infections
Sickle Cells Disease

Interventions

BIOLOGICAL: Vaccination with the combined vaccine (Prevenar13 ®)
BIOLOGICAL: Vaccination with the polysaccharide vaccine (Pneumo 23 ®)

Sponsor

Assistance Publique - Hôpitaux de Paris